Marie Paule Kieny
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marie Paule Kieny has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
Ana Maria Henao-Restrepo
Initiative for Vaccine Research, Immunization, Vaccines and Biologicals, World Health Organization, Switzerland
3 shared publications- Vasee Moorthy
WHO, 1211 Geneva, Switzerland
3 shared publications Delanyo Dovlo
Regional Office for Africa, World Health Organization, Brazzaville, Congo
2 shared publicationsIra M Longini
Department of Biostatistics, University of Florida, Gainesville, FL, USA
2 shared publicationsJoachim Hombach
Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland
2 shared publicationsJohn-Arne Røttingen
Norwegian Institute of Public Health, Division of Infectious Disease Control, Oslo, Norway; Institute of Health and Society, University of Oslo, Oslo, Norway; Harvard T H Chan School of Public Health, Boston, MA, USA
2 shared publications
Latest Publications
- Open Access
- 1 July 2017
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 95 (7) , 484
Systems science for universal health coverage
- 1 July 2017
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 95 (7) , 484
Open AccessSystems science for universal health coverage
- 1 June 2017
- Published by Elsevier in The Lancet
- Vol. 389 (10088) , 2469-2470
WHO R&D Blueprint: a global coordination mechanism for R&D preparedness
- 1 June 2017
- Published by Elsevier in The Lancet
- Vol. 389 (10088) , 2469-2470
WHO R&D Blueprint: a global coordination mechanism for R&D preparedness
- Top Cited PapersOpen Access
- 7 April 2017
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 95 (7) , 537-539
Strengthening health systems for universal health coverage and sustainable development
- 7 April 2017
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 95 (7) , 537-539
Top Cited PapersOpen AccessStrengthening health systems for universal health coverage and sustainable development
- Open Access
Developing a vaccine against Zika
We’ve made a good start but substantial challenges remain The race to develop a vaccine against Zika began in February 2016, when the unusual clustering of cases of microcephaly and other neurological disorders associated with Zika virus infection led to the declaration of a public health emergency of international concern. When the World Health Organization held its first consultation in March, 14 active vaccine projects had already been announced.1 Today, WHO’s pipeline tracker counts about 30 active projects, pursued by developers from endemic and non-endemic countries, private and public sector.2 Such a jump start in vaccine development is rare, and several candidates have already progressed to clinical development. This pace is facilitated by our collective experience in developing vaccines against flaviviruses, the availability of novel vaccine technologies that greatly facilitate manufacturing of vaccines appropriate for trials in humans, and generous funding from some governments to support both basic research and product development. However, there is no guarantee that the pace we have seen in early development …
Open AccessDeveloping a vaccine against Zika
We’ve made a good start but substantial challenges remain The race to develop a vaccine against Zika began in February 2016, when the unusual clustering of cases of microcephaly and other neurological disorders associated with Zika virus infection led to the declaration of a public health emergency of international concern. When the World Health Organization held its first consultation in March, 14 active vaccine projects had already been announced.1 Today, WHO’s pipeline tracker counts about 30 active projects, pursued by developers from endemic and non-endemic countries, private and public sector.2 Such a jump start in vaccine development is rare, and several candidates have already progressed to clinical development. This pace is facilitated by our collective experience in developing vaccines against flaviviruses, the availability of novel vaccine technologies that greatly facilitate manufacturing of vaccines appropriate for trials in humans, and generous funding from some governments to support both basic research and product development. However, there is no guarantee that the pace we have seen in early development …
- 1 July 2016
- Published by Elsevier in The Lancet
- Vol. 388 (10043) , 460-461
The need for global R&D coordination for infectious diseases with epidemic potential
- 1 July 2016
- Published by Elsevier in The Lancet
- Vol. 388 (10043) , 460-461
The need for global R&D coordination for infectious diseases with epidemic potential
- 1 April 2016
- Published by Elsevier in Current Opinion in Virology
- Vol. 17, 138-144
On a path to accelerate access to Ebola vaccines: The WHO's research and development efforts during the 2014–2016 Ebola epidemic in West Africa
- 1 April 2016
- Published by Elsevier in Current Opinion in Virology
- Vol. 17, 138-144
On a path to accelerate access to Ebola vaccines: The WHO's research and development efforts during the 2014–2016 Ebola epidemic in West Africa
- 1 April 2016
- Published by Elsevier in The Lancet
- Vol. 387 (10027) , 1509-1510
Changes in the primary outcome in Ebola vaccine trial – Authors' reply
- 1 April 2016
- Published by Elsevier in The Lancet
- Vol. 387 (10027) , 1509-1510
Changes in the primary outcome in Ebola vaccine trial – Authors' reply
- Open Access
- 1 April 2016
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 94 (4) , 234-234A
Best practices for sharing information through data platforms: establishing the principles
- 1 April 2016
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 94 (4) , 234-234A
Open AccessBest practices for sharing information through data platforms: establishing the principles
- 1 March 2016
- Published by Elsevier in The Lancet
- Vol. 387 (10024) , 1157
Global platform to inform investments for health R&D
- 1 March 2016
- Published by Elsevier in The Lancet
- Vol. 387 (10024) , 1157
Global platform to inform investments for health R&D
- Top Cited Papers
- 1 August 2015
- Published by Elsevier in The Lancet
- Vol. 386 (9996) , 857-866
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial
- 1 August 2015
- Published by Elsevier in The Lancet
- Vol. 386 (9996) , 857-866
Top Cited PapersEfficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial